PRODUCTS & SERVICES
Despite the availability of vaccination, rapid and accurate diagnosis of COVID-19 will be a key tool for long term control of COVID-19 spreading and emergence of outbreaks. According to Pavol Čekan, CEO of MultiplexDX, the European Union's support for R&D in this area is important not only in Slovakia, but also within the pan-European research network. During her visit to the Comenius University Science Park, the President of the European Commission, Ursula von der Leyen, took interest in both the latest gargle LAMP tests, as well as the upcoming mobile testing.
Mrs. von der Leyen’s visit to MultiplexDX laboratories taking place on June 21st, 2021, was marked by the occasion of approving Slovakia’s Recovery and Resilience Plan submitted previously for review to the EC. This was later announced at a joint press conference with Slovak Prime Minister Mr. Eduard Heger.
EC President Mrs. von der Leyen, who, in addition to studying medicine, also worked in the field of research at the epidemiology department at the German Medizinische Hochschule Hannover, was presented the latest solution for mobile testing by LAMP tests.
"After more than a year with COVID, there is a clear trend in diagnostics. Not only to increases the accuracy, but also the speed and mobility of testing. That is why, together with our partner, International Rescue Systems, we have developed mobile test units, where, of course, we use our own LAMP tests,”
adds P. Čekan.
This is because the LAMP tests developed and manufactured by MultiplexDX achieve an accuracy approaching that of PCR tests. At the same time, the complexity and speed of their evaluation is close to that of antigen tests, as they do not require demanding laboratory equipment, but the result can be obtained in the range of 30-55 minutes in a mobile laboratory.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.